GETECCU|Publicaciones del Grupo

Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.

Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP; SEGURTB study group from GETECCU. [PubMed – indexed for MEDLINE]

Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.

Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU). [PubMed – indexed for MEDLINE]

Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn’s disease patients treated with infliximab.

Hernández-Breijo B, Chaparro M, Cano-Martínez D, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Gisbert JP, Guijarro LG; PREDICROHN study group from GETECCU. [PubMed – indexed for MEDLINE]

Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.

Carpio D, Jauregui-Amezaga A, de Francisco R, de Castro L, Barreiro-de Acosta M, Mendoza JL, Mañosa M, Ollero V, Castro B, González-Conde B, Hervías D, Sierra Ausin M, Sancho Del Val L, Botella-Mateu B, Martínez-Cadilla J, Calvo M, Chaparro M, Ginard D, Guerra I, Maroto N, Calvet X, Fernández-Salgado E, Gordillo J, Rojas Feria M; GETECCU. [PubMed – indexed for MEDLINE]

Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry.

Gordillo J, Cabré E Garcia-Planella E, Ricart E, Ber-Nieto Y, Márquez L, Rodríguez-Moranta F, Ponferrada Á, Vera I, Gisbert JP, Barrio J, Esteve M, Merino O, Muñoz F, Domènech E; ENEIDA Project of the Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU). [PubMed – indexed for MEDLINE]

Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).

Loras C, Gisbert JP, Saro MC, Piqueras M, Sánchez-Montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-Bañares F, Esteve M; REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). [PubMed – indexed for MEDLINE]

Risk of colectomy in patients with ulcerative colitis under thiopurine treatment.

Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García-Sanchez V, Marín-Jiménez I, Rodriguez-Moranta F, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Iborra M, Gutiérrez A, Vera M, Andreu M; Spanish GETECCU group (ENEIDA project). [PubMed – indexed for MEDLINE]

Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database.

Cabré E, Mañosa M, García-Sánchez V, Gutiérrez A, Ricart E, Esteve M, Guardiola J, Aguas M, Merino O, Ponferrada A, Gisbert JP, Garcia-Planella E, Ceña G, Cabriada JL, Montoro M, Domènech E; ENEIDA Project of the Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU) [PubMed – indexed for MEDLINE]

Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU.

Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. [PubMed – indexed for MEDLINE]

Disease severity in familial cases of IBD.

Andreu M, Márquez L, Domènech E, Gisbert JP, García V, Marín-Jiménez I, Peñalva M, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Nos P, Gutiérrez A, Vera I, Cabriada JL, Martín MD, Cañas-Ventura A, Panés J; Spanish GETECCU group (ENEIDA project). [PubMed – indexed for MEDLINE]

Smoking does influence disease behaviour and impacts the need for therapy in Crohn’s disease in the biologic era.

Nunes T, Etchevers MJ, Domènech E, García-Sánchez V, Ber Y, Peñalva M, Merino O, Nos P, Garcia-Planella E, Casbas AG, Esteve M, Taxonera Samsó C, Montoro Huguet M, Gisbert JP, Martín Arranz MD, García-Sepulcre MF, Barreiro-de Acosta M, Beltrán B, Alcaide Suárez N, Saro Gismera C, Cabriada JL, Cañas-Ventura A, Gomollón F, Panés J; Tobacco-Eneida Study Group of GETECCU. [PubMed – indexed for MEDLINE]

Impact of current smoking on the clinical course of microscopic colitis.

Fernández-Bañares F, de Sousa MR, Salas A, Beltrán B, Piqueras M, Iglesias E, Gisbert JP, Lobo B, Puig-Diví V, García-Planella E, Ordás I, Andreu M, Calvo M, Montoro M, Esteve M, Viver JM; RECOMINA Project, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). [PubMed – indexed for MEDLINE]

Reccomendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease.

Gomollón F, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; en representación de GETECCU.[PubMed – indexed for MEDLINE] – Elsevier

Inflammatory bowel disease patient’s satisfaction with healthcare services received. Physicians’ and nurses’ perceptions.

Casellas F, Vera I, Ginard D, Torrejón A; Grupo Español de Trabajo En Enfermedad de Crohn Y Colitis Ulcerosa (GETECCU). Inflammatory bowel disease patient’s satisfaction with healthcare services received. Physicians’ and nurses’ perceptions. Rev Esp Enferm Dig. 2013 Aug;105(7):385-9.  [PubMed – indexed for MEDLINE]

Development and testing of a new instrument to measure patient satisfaction with health care in inflammatory bowel disease: the CACHE questionnaire.

Casellas F, Ginard D, Vera I, Torrejón A; GETECCU. Development and testing of a new instrument to measure patient satisfaction with health care in inflammatory bowel disease: the CACHE questionnaire. Inflamm Bowel Dis. 2013 Mar;19(3):559-68.   [PubMed – indexed for MEDLINE]

Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry.

J. L. Cabriada E. Domenech  N. Ibargoyen V. Hernandez  J. Clofent  D. Ginard I. Gutierrez-Ibarluzea J. Hinojosa. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol (2012) 47:359–365.  [PubMed – indexed for MEDLINE]

Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study.

Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M;
REPENTINA study, Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa.
Am J Gastroenterol. 2009 Jan;104(1):57-63.
PMID: 19098850 [PubMed – indexed for MEDLINE]


Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab: 2006 update.

López-San Román A, Obrador A, Fortún J, Muñoz P, Gassull MA;
Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Gastroenterol Hepatol. 2006 Feb;29(2):81-4. Spanish. No abstract available.
PMID: 16448610 [PubMed – indexed for MEDLINE]


GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease

Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull MA;
Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa.
Gastroenterol Hepatol. 2005 Mar;28(3):126-34. Review. Spanish. No abstract available.
PMID: 15771858 [PubMed – indexed for MEDLINE]


Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA;
Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU).
Aliment Pharmacol Ther. 2004 Dec;20(11-12):1347-52.
PMID: 15606397 [PubMed – indexed for MEDLINE]


Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab.

Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA;
Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
Spanish Working Group on Crohn Disease and Ulcerative Colitis
Gastroenterol Hepatol. 2003 Jan;26(1):29-33. Review. Spanish. No abstract available.
PMID: 12525326 [PubMed – indexed for MEDLINE]


Recommendations for the use of infliximab (Remicade) in Crohn’s disease. GETECCU 2001

Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA;
Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa(GETECCU).
Gastroenterol Hepatol. 2002 Mar;25(3):162-9. Spanish. No abstract available.
PMID: 11864540 [PubMed – indexed for MEDLINE]


Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis.

Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné JJ, Moles J, Gomollón F, Gassull MA.
Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU).
Am J Gastroenterol. 1999 Feb;94(2):427-33.
PMID: 10022641 [PubMed – indexed for MEDLINE]

Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease

Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; en representación del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Gastroenterol Hepatol. 2013 Mar;36(3):127-46. [PubMed – indexed for MEDLINE]

Epidemiological Risk Factors in Microscopic Colitis: A Prospective Case-Control Study

Fernández-Bañares F, de Sousa MR, Salas A, Beltrán B, Piqueras M, Iglesias E, Gisbert JP, Lobo B, Puig-Diví V, García-Planella E, Ordás I, Andreu M, Calvo M, Montoro M, Esteve M, Viver JM; for the RECOMINA Project, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Inflamm Bowel Dis. 2013 Feb;19(2):411-417. [PubMed – indexed for MEDLINE]

Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU

Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J. Gastroenterol Hepatol. 2013 Feb;36(2):104-14. [Enlace de descarga]

High smoking cessation rate in Crohn’s disease patients after physician advice–the TABACROHN Study

Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Martí E, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; TABACROHN Study Group of GETECCU. J Crohns Colitis. 2013 Apr 1;7(3):202-7. [PubMed – indexed for MEDLINE]

Does Smoking Influence Crohn’s Disease in the Biologic Era? The TABACROHN Study

Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Acosta MB, Bastida G, García S, Gento E, Ginard D, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M; for the TABACROHN Study Group of GETECCU, Spanish Working Group in Crohnʼs Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2013 Jan;19(1):23-29. [PubMed – indexed for MEDLINE]

Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series

Barreiro-de Acosta M, García-Bosch O, Gordillo J, Mañosa M, Menchén L, Souto R, Marin-Jimenez I; Grupo Joven GETECCU.Eur J Gastroenterol Hepatol. 2012 Jul;24(7):756-8. [PubMed – indexed for MEDLINE]

Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study

Barreiro-de Acosta M, García-Bosch O, Souto R, Mañosa M, Miranda J, García-Sanchez V, Gordillo J, Chacon S, Loras C, Carpio D, Maroto N, Menchén L, Rojas-Feria M, Sierra M, Villoria A, Marin-Jimenez I; Grupo joven GETECCU. Inflamm Bowel Dis. 2012 May;18(5):812-7.  [PubMed – indexed for MEDLINE]

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients

González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP; “Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)”. Aliment Pharmacol Ther. 2011 Sep;34(5):544-54.  [PubMed – indexed for MEDLINE]

Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study

Nunes T, Barreiro-de Acosta M, Nos P, Marin-Jiménez I, Bermejo F, Ceballos D, Iglesias E, Gomez-Senent S, Torres Y, Ponferrada A, Arevalo JA, Hernandez V, Calvet X, Ginard D, Monfort D, Chaparro M, Manceñido N, Domínguez-Antonaya M, Villalón C, Perez-Calle JL, Muñoz C, Nuñez H, Carpio D, Aramendiz R, Bujanda L, Estrada-Oncins S, Hermida C, Barrio J, Casis MB, Dueñas-Sadornil MC, Fernández L, Calvo-Cenizo MM, Botella B, de Francisco R, Ayala E, Sans M; RECLICU Study Group of GETECCU. J Crohns Colitis. 2010 Dec;4(6):629-36. [PubMed – indexed for MEDLINE]

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Gut. 2010 Oct;59(10):1340-6. [PubMed – indexed for MEDLINE]

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease

Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, Gomollón F, Rodrigo L, Calvet X, Esteve M, García-Planella E, García-López S, Taxonera C, Calvo M, López M, Ginard D, Gómez-García M, Garrido E, Pérez-Calle JL, Beltrán B, Piqueras M, Saro C, Botella B, Dueñas C, Ponferrada A, Mañosa M, García-Sánchez V, Maté J, Gisbert JP. Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15.PMID:23318480. [PubMed – indexed for MEDLINE]

Effectiveness of infliximab after adalimumab failure in Crohn’s disease

Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP.World J Gastroenterol. 2012 Oct 7;18(37):5219-24. doi: 10.3748/wjg.v18.i37.5219. PMID: 23066316. [PubMed – indexed for MEDLINE]

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study

Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, Gisbert JP. Aliment Pharmacol Ther. 2012 Jan;35(2):275-83. doi: 10.1111/j.1365-2036.2011.04934.x. Epub 2011 Dec 5. PMID: 22142227. [PubMed – indexed for MEDLINE]

Long-term durability of response to adalimumab in Crohn’s disease

Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP. Inflamm Bowel Dis. 2012 Apr;18(4):685-90. doi: 1. Farrell RJ, Peppercorn M a. Ulcerative colitis. Lancet [Internet]. 2002 Jan 26;359(9303):331–40. [PubMed – indexed for MEDLINE]

Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response

Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP. J Clin Gastroenterol. 2011 Feb;45(2):113-8. doi: 10.1097/MCG.0b013e3181ebaef9. PMID:  21242747. [PubMed – indexed for MEDLINE]

Satisfaction of health care professionals managing patients with inflammatory bowel disease

Casellas F, Ginard D, Vera I, Torrejón A; on behalf of the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). J Crohns Colitis. 2012 Nov 5. doi:pii: S1873-9946(12)00425-4. 10.1016/j.crohns.2012.10.003. [PubMed – indexed for MEDLINE]

Diferencias en el curso de la Enfermedad Inflamatoria Intestinal según la agregación familiar.

M Andreu. Enlace al artículo en PUBMED

Efecto del tabaquismo en el fenotipo de la Enfermedad de Crohn.

J Etchevers. Enlace al artículo en PUBMED

“Intensificación” de la dosis de infliximab en la enfermedad de Crohn: frecuencia y eficacia a largo plazo.

JP Gisbert. Enlace al artículo en PUBMED.

Estudio de asociación de genoma completo en las enfermedades mediadas por mecanismos autoinmunes (IMID).

E Ricart. Enlace al artículo en PUBMED.

Concordancia en la presentación y evolución clínica en formas familiares de EII.

E Domènech. Enlace al artículo en PUBMED

“Intensificación” de la dosis de adalimumab en la enfermedad de Crohn: frecuencia y eficacia a largo plazo.

JP Gisbert. Enlace al artículo en PUBMED.

Eficacia del tratamiento con Adalimumab en la colitis ulcerosa en pacientes con fracaso previo de infliximab. Un estudio observacional.

O García-Bosch. Enlace al artículo en PUBMED.

Búsqueda de factores genéticos asociados a la eficacia y toxicidad del tratamiento con tiopurínicos en pacientes con enfermedad inflamatoria intestinal.

JP Gisbert.  Enlace al artículo en PUBMED.

 

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Mañosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Márquez L, Prieto V, García-Sánchez V, Guardiola J, Rodriguez GE, Martín-Arranz MD, García-Tercero I, Sicilia B, Masedo Á, Lorente R, Rivero M, Fernández-Salazar L, Gutiérrez A, Van Domselaar M, López-SanRomán A, Ber Y, García-Sepulcre M, Ramos L, Bermejo F, Gisbert JP; Spanish GETECCU group (ENEIDA project). Inflamm Bowel Dis. 2016 Apr;22(4):894-901. Enlace al artículo en PUBMED

 

 

 

última actualización: 18 de Abril de 2017 12:39
Nuestros patrocinadores|lea nuestra política de patrocinio